Considering the beneficial effects of the reduced transporting activity of INDY on metabolism and health, we and others have suggested mIndy (SLC13A5) as a target for the treatment of metabolic disorders (Figure 1; Rogina et al., 2000; Birkenfeld et al., 2011; Frankel and Rogina, 2012; Willmes and Birkenfeld, 2013; Rogers and Rogina, 2015). Here, SLC13A5 is linked to metabolic disease.